Kenneth E. Robertson

Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group.

Edward J. Bastyr, CA Stuart, Robert G. Brodows et al. · Diabetes Care · 2000 · 275 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +17

Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial

Bernhard Ludvik, Juan P. Frías, Francisco J. Tinahones et al. · The Lancet Diabetes & Endocrinology · 2018 · 261 citations · Full text

Medicine, Endocrinology, Pharmacology +16

The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus

Sidney Rosenblatt, Barry Miskin, N. Bradly Glazer et al. · Coronary Artery Disease · 2001 · 221 citations

Medicine, Pharmacology, Pharmacotherapy +17

Effects of the Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist Dulaglutide on Ambulatory Blood Pressure and Heart Rate in Patients With Type 2 Diabetes Mellitus

Keith C. Ferdinand, William B. White, David A. Calhoun et al. · Hypertension · 2014 · 143 citations

Medicine, Pharmacology, Pharmacotherapy +17

A 24‐week study to evaluate the efficacy and safety of once‐weekly dulaglutide added on to glimepiride in type 2 diabetes ( <scp>AWARD</scp> ‐8)

Kathleen Dungan, Raimund Weitgasser, Federico Pérez Manghi et al. · Diabetes Obesity and Metabolism · 2016 · 99 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17